Ligand Pharmaceuticals (NASDAQ:LGND) is scheduled to post its quarterly earnings results before the market opens on Thursday, November 8th. Analysts expect Ligand Pharmaceuticals to post earnings of $0.84 per share for the quarter. Ligand Pharmaceuticals has set its FY18 guidance at ~$6.30 EPS.
Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings data on Monday, August 6th. The biotechnology company reported $2.59 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.34 by $0.25. Ligand Pharmaceuticals had a return on equity of 25.95% and a net margin of 52.10%. The company had revenue of $90.00 million during the quarter, compared to analysts’ expectations of $82.20 million. During the same period last year, the firm posted $0.67 earnings per share. The business’s revenue was up 221.4% on a year-over-year basis. On average, analysts expect Ligand Pharmaceuticals to post $6 EPS for the current fiscal year and $5 EPS for the next fiscal year.
LGND opened at $164.81 on Thursday. Ligand Pharmaceuticals has a 12-month low of $126.50 and a 12-month high of $278.62. The company has a market capitalization of $3.53 billion, a PE ratio of 64.13, a price-to-earnings-growth ratio of 1.46 and a beta of 1.06. The company has a quick ratio of 2.32, a current ratio of 2.34 and a debt-to-equity ratio of 0.96.
In other Ligand Pharmaceuticals news, SVP Charles S. Berkman sold 19,417 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $254.99, for a total transaction of $4,951,140.83. Following the transaction, the senior vice president now owns 28,232 shares in the company, valued at approximately $7,198,877.68. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John W. Kozarich sold 2,500 shares of the firm’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $275.04, for a total value of $687,600.00. Following the transaction, the director now owns 26,142 shares in the company, valued at approximately $7,190,095.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 119,922 shares of company stock worth $30,297,452. Corporate insiders own 7.80% of the company’s stock.
Several analysts recently weighed in on LGND shares. HC Wainwright lifted their price target on Ligand Pharmaceuticals from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, October 2nd. Roth Capital raised Ligand Pharmaceuticals from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $250.00 to $195.00 in a report on Monday. BidaskClub cut Ligand Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 19th. Argus set a $300.00 price target on Ligand Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 11th. They noted that the move was a valuation call. Finally, Goldman Sachs Group started coverage on Ligand Pharmaceuticals in a report on Friday, August 17th. They set a “neutral” rating and a $256.00 price target for the company. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $226.88.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
See Also: Stock Split
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.